Missions

Promote and enhance a research technology park dedicated to life sciences

The Biocitech technology park for life sciences offers a world-class environment and services for the development of biotechnology, biopharmaceutical and fine chemical companies.
Biocitech is on the outskirts of Paris, only 20 minutes from both the city centre and Charles de Gaulle airport. It is privately owned and provides secure premises and comprehensive facilities based on the latest technology. It has received regulatory approval for conformity to environmental protection standards. Companies can use one or many of the services offered. These include office space, laboratories and a range of technical and scientific services, - all designed to let entrepreneurs focus their time and resources on their core business.

Companies already established at Biocitech represent a wide variety of complementary disciplines and many are working on collaborative projects.

Participate to the development of Biotechnology

Biocitech is strongly involved in the development of Paris Region Bio cluster.
Along with other organizations in the Ile-de-France region around Paris, Biocitech plays a key role in the Medicen Paris Region network. This is a healthcare and new therapy cluster designated by the French government as internationally competitive and hence qualified for special privileges.
Companies involved in Medicen projects are:

  • The Chimiothèque Project, infections
    Piloted by Novexel, Mutabilis is a member
  • The Ingénis Project, molecular and cellular therapy: genomic engineering for the health industry
    Piloted by Cellectis
  • The Biotype Project, molecular and cellular therapy: molecular and multidimensional cellular biotyping
    Sibio is a member
  • The Modexa Project, infections: new models of experimental infections
    Piloted by Mutabilis, Oroxcell is a member
  • The D2P Project « Drug Design Platform », the science and techniques of drugs
    Mutabilis is a member
  • The  Dosca Project, Oncology – Development of synthetic oligosaccharides
         Piloted by Endotis
         Roowin is a member
  • The TMB Project , Sciences and techniques of the medicine – new predictive models against the pain
         Piloted by Oroxcell
  • The  HORUS Project, Sciences and techniques of the medicine – development of anti-thrombotics
                Endotis is a member